CHRNA2 genetic markers associated with galantamine response
Details for Australian Patent Application No. 2004269323 (hide)
International Classifications
Event Publications
9 February 2006 PCT application entered the National Phase
PCT publication WO2005/021796 Priority application(s): WO2005/021796
29 November 2007 Assignment before Grant
Genaissance Pharmaceuticals, Inc. The application has been assigned to PGxHealth, LLC
11 February 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2004269335-Multi-allelic molecular detection of SARS-associated coronavirus
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser